Hiding in Plain Sight: Revisiting a Case of Antitubercular Drug Induced Chromaturia
Article Sidebar
Antitubercular Drugs,
Adverse Drug Reactions
Main Article Content
Abstract
India being a developing country has a high burden of Tuberculosis (TB). It is a communicable disease and a major global heath challenge. Considering the impact of this illness on both individual patients and public health, it is critical to comprehend the effectiveness and adverse pharmacological profile of the medications. Although most patients on a daily ATT regimen do not encounter the documented ADRs listed below, doctors and patients should be concerned about them. For example, rifampicin induced discoloration of body fluids is often overlooked as it is "innocuous". Nonetheless, Adverse drug reaction (ADRs) reports on these drugs are scarce in proportion especially in regards to the most common ADRs like antitubercular treatment (ATT) induced chromaturia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Adams, R. A., Leon, G., Miller, N. M., Reyes, S. P., Thantrong, C. H., Thokkadam, A. M., & Brynildsen, M. P. (2021). Rifamycin antibiotics and the mechanisms of their failure. The Journal of antibiotics, 74(11), 786-798.
Beloor Suresh A, Rosani A, Patel P, et al. Rifampin. [Updated 2023 Nov 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/nbk55748.
Chauhan, A., Parmar, M., Dash, G. C., Solanki, H., Chauhan, S., Sharma, J., ... & Pati, S. (2023). The prevalence of tuberculosis infection in India: A systematic review and meta-analysis. Indian Journal of Medical Research, 157(2&3), 135-151.
Coleman JJ & Pontefract SK. Adverse drug reactions. Clin Med 2016;16(5):481–5.
Koratala, A., Chamarthi, G., & Segal, M. S. (2018). Not all that is red is blood: a curious case of chromaturia. Clinical case reports, 6(6).
Michael, O. S., Sogaolu, O. M., Fehintola, F. A., Ige, O. M., & Falade, C. O. (2016). Adverse events to first line anti-tuberculosis drugs in patients co-infected with HIV and tuberculosis. Annals of Ibadan postgraduate medicine, 14(1), 21-29.
Morgan, J. R., Clarke, K. W., & Brear, S. G. (1993). Reply to the letter from Dr Miller. Respiratory Medicine, 87(4), 320-321.
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., ... & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 30(2), 239-245.
Rothstein, D. M. (2016). Rifamycins, alone and in combination. Cold Spring Harbor Perspectives in Medicine, 6(7), a027011.
Sankar, K. H., Roch, K., Jom, D., Palappallil, D. S., Panattil, P., & Sankaranarayanan, R. K. (2022). Adverse drug reaction profile of daily regimen antituberculosis treatment. Perspectives in Clinical Research, 13(4), 194-198.
Siddhu, C. K., Joseph, G., Bhatti, N., & Badyal, D. (2023). Paracetamol induced facial puffiness: An uncommon case report. National Journal of Pharmacology and Therapeutics, 1(3), 170-172.
Sotgiu, G., Centis, R., D’ambrosio, L., & Migliori, G. B. (2015). Tuberculosis treatment and drug regimens. Cold Spring Harbor perspectives in medicine, 5(5), a017822.
Szipszky, C., Van Aartsen, D., Criddle, S., Rao, P., Zentner, I., Justine, M., & Heysell, S. K. (2021). Determination of rifampin concentrations by urine colorimetry and mobile phone readout for personalized dosing in tuberculosis treatment. Journal of the Pediatric Infectious Diseases Society, 10(2), 104-111.